Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Fibrosarcoma Therapeutics Report 2016 - Pipeline Review of 8 Companies & 12 Molecules - Research and Markets

Research and Markets
Posted on: 20 Sep 16

Research and Markets has announced the addition of the "Fibrosarcoma - Pipeline Review, H2 2016" report to their offering.

Fibrosarcoma pipeline therapeutics constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by Companies and remaining by the Universities

Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Fibrosarcoma Fibrosarcoma is a malignant tumor derived from fibrous connective tissue. Symptoms include local pain, local swelling, local warmth, dilated blood vessels pain and swelling of the bone, pathological fractures, neurological and vascular changes.

Fibrosarcoma - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Fibrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Fibrosarcoma and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Fibrosarcoma Overview
  3. Therapeutics Development
  4. Pipeline Products for Fibrosarcoma - Overview
  5. Pipeline Products for Fibrosarcoma - Comparative Analysis
  6. Fibrosarcoma - Therapeutics under Development by Companies
  7. Fibrosarcoma - Therapeutics under Investigation by Universities/Institutes
  8. Fibrosarcoma Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Fibrosarcoma - Products under Development by Companies
  13. Fibrosarcoma - Products under Investigation by Universities/Institutes
  14. Fibrosarcoma - Companies Involved in Therapeutics Development
  • Advanced Proteome Therapeutics Corporation
  • Advenchen Laboratories, LLC
  • Daiichi Sankyo Company, Limited
  • Elsalys Biotech SAS
  • Millennium Pharmaceuticals Inc
  • Novartis AG
  • Rigontec GmbH
  • Sumitomo Dainippon Pharma Co., Ltd.

For more information about this report visit

Related Topics: Oncology Drugs

View source version on

Business Wire

Last updated on: 20/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.